Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production

被引：139

作者：

Clark, MP ^{[1
]}

Laughlin, SK ^{[1
]}

Laufersweiler, MJ ^{[1
]}

Bookland, RG ^{[1
]}

Brugel, TA ^{[1
]}

Golebiowski, A ^{[1
]}

Sabat, MP ^{[1
]}

Townes, JA ^{[1
]}

VanRens, JC ^{[1
]}

Djung, JF ^{[1
]}

Natchus, MG ^{[1
]}

De, B ^{[1
]}

Hsieh, LC ^{[1
]}

Xu, SC ^{[1
]}

Walter, RL ^{[1
]}

Mekel, MJ ^{[1
]}

Heitmeyer, SA ^{[1
]}

Brown, KK ^{[1
]}

Juergens, K ^{[1
]}

Taiwo, YO ^{[1
]}

Janusz, MJ ^{[1
]}

机构：

[1] Procter & Gamble Pharmaceut, Mason, OH 45040 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 11期

关键词：

D O I：

10.1021/jm049968m

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

2-Aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel bicyclic pyrazolope core, are described. Many showed low-nanomolar activity against lipopolysaccharide-induced TNF-alpha production in monocytic cells. Secondary screening data are presented for the pyrimidinyl bicyclic pyrazolones. Several of these analogues showed good oral bioavailability in rat and efficacy in the rat iodoacetate in vivo model.

引用

页码：2724 / 2727

页数：4

共 14 条

[1]

Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079-6468(08)70091-2

[2] 5-(3-CARBOXYMETHOXYPHENYL)-2-(4,5-DIMETHYLTHIAZOLYL)-3-(4-SULFOPHENYL)TETRAZOLIUM, INNER SALT (MTS) AND RELATED ANALOGS OF 3-(4,5-DIMETHYLTHIAZOLYL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE (MTT) REDUCING TO PURPLE WATER-SOLUBLE FORMAZANS AS CELL-VIABILITY INDICATORS [J].

BARLTROP, JA ;

OWEN, TC ;

CORY, AH ;

CORY, JG .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (11) :611-&

[3] Cytokines in autoimmunity [J].

Brennan, FM ;

Feldmann, M .

CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (06) :872-877

[4] The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis [J].

Camussi, G ;

Lupia, E .

DRUGS, 1998, 55 (05) :613-620

[5] MAP kinases [J].

Chen, Z ;

Gibson, TB ;

Robinson, F ;

Silvestro, L ;

Pearson, G ;

Xu, BE ;

Wright, A ;

Vanderbilt, C ;

Cobb, MH .

CHEMICAL REVIEWS, 2001, 101 (08) :2449-2476

[6]

CLARK MP, 2003, Patent No. 0324971

[7] 2,4,5-TRIARYLIMIDAZOLE INHIBITORS OF IL-1 BIOSYNTHESIS [J].

GALLAGHER, TF ;

FIERTHOMPSON, SM ;

GARIGIPATI, RS ;

SORENSON, ME ;

SMIETANA, JM ;

LEE, D ;

BENDER, PE ;

LEE, JC ;

LAYDON, JT ;

GRISWOLD, DE ;

CHABOTFLETCHER, MC ;

BRETON, JJ ;

ADAMS, JL .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (11) :1171-1176

[8] Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase [J].

Liverton, NJ ;

Butcher, JW ;

Claiborne, CF ;

Claremon, DA ;

Libby, BE ;

Nguyen, KT ;

Pitzenberger, SM ;

Selnick, HG ;

Smith, GR ;

Tebben, A ;

Vacca, JP ;

Varga, SL ;

Agarwal, L ;

Dancheck, K ;

Forsyth, AJ ;

Fletcher, DS ;

Frantz, B ;

Hanlon, WA ;

Harper, CF ;

Hofsess, SJ ;

Kostura, M ;

Lin, J ;

Luell, S ;

O'Neill, EA ;

Orevillo, CJ ;

Pang, M ;

Parsons, J ;

Rolando, A ;

Sahly, Y ;

Visco, DM ;

O'Keefe, SJ .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (12) :2180-2190

[9] The protein kinase complement of the human genome [J].

Manning, G ;

Whyte, DB ;

Martinez, R ;

Hunter, T ;

Sudarsanam, S .

SCIENCE, 2002, 298 (5600) :1912-+

[10] PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOR-NECROSIS-FACTOR PROCESSING [J].

MOHLER, KM ;

SLEATH, PR ;

FITZNER, JN ;

CERRETTI, DP ;

ALDERSON, M ;

KERWAR, SS ;

TORRANCE, DS ;

OTTENEVANS, C ;

GREENSTREET, T ;

WEERAWARNA, K ;

KRONHEIM, SR ;

PETERSEN, M ;

GERHART, M ;

KOZLOSKY, CJ ;

MARCH, CJ ;

BLACK, RA .

NATURE, 1994, 370 (6486) :218-220

← 1 2 →